References
- Horlzer D., Ganser A., Heimpel H. “Atypical” leukemias: Preleukemia, smouldering leukemia and hypoplastic leukemia: Recent results. Cancer. Res. 1984; 93: 69–101
- Geishler K., Hinterherger W., Bettelheim P. Colony growth characteristics in chronic myclomonocytic lcukemia. Leuk Res 1988; 12: 373–377
- Bonfichi M., Bernasconi P., Alessandrino E. P., Brunetti A., Boni M., Brera C., Castelli G., Lazzarino M., Bernasconi C. Prognostic significance of bone marrow CFU-GM and cytogenetic studies in primary myelodiaplastic syndromes (MDS). Leuk, Res. 1991; 15: 29
- Nagler A., Binet C., Mac Kichan M. L., Negrin R., Bangs D., Donlon T., Greenberg P. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodisplustic syndromes: comparison between recombinant human granulocyte granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF. Blood 1990; 76(7)1299–1307
- Nagler A., Ginzton N., Negrin R., Bangs D., Donlon T., Greenberg P. Effects of recombinant human granulocyte colony stimulating factor on in vitro hemopoicsis in the myelodisplastic syndromes. Leukemia 1990; 4: 193–202
- Nagler A., MacKichan M. L., Negrin K., Donlon T., Greenberg P. L. Effects of granulocyte colony-stirnulating factor on in vitro heinopoiesis in the myelodisplastic syndromes. Leukemia 1995; 9: 30–39
- Greenberg P. L., Negrin K., Ginzton N. G-CSF synergixs with erythropoictin (EPO) for enhancing crythroid colony-formation (BFLJ-E) in myelodisplastic syndromes (MDS). Blood 1991; 78: 38a, (suppl)
- Nagler A., Ginzton N., Negrin R. S., Donlon T., Souza L., Greenberg P. L. In vitro effects of recombinant human granulocyte (G-CSF) and granulocyte-monocyte (GM-CSF) colony stimulating factors on hematopoiesys in the myelodysplastic syndromes. Blood 1988; 72: 128
- Mayani H., Baines P., Bowen D. T., Jacobs A. In vitro growth of myeloid and erythroid progenitor cells from mylodisplastic palients in response to recombinant human granulocyte-macrophage colony stimulating factor. Leukelli 1989; 3: 29–32
- Pierelli L., Menichella G., Scambia G., Teofili L., Lovino S., Scrafini R., Benedetti Paniei P., Salerno G., Rumi C., Zini G., d'Onofrio G., Leone G., Mancuso S., Bizzi B. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haeniopoietic progenitor cells. Bone Marrow Transplant 1994; 14: 23–30
- Soligo D. A., Campiglio S., Servue F., Bossolasco P., Romiti L., Cortellezzi A., Lambertenghi-Deliliers G. Responsc of myclodisplastic syndrome marrow progenitor cells to stimulation with cytokine combinations in a stroma-free long-term culture system. Br. J. Haematol 1996; 92: 548–551
- Backx B., Broeders L., Lowenberg B. Kit-ligand improves erythropoicsys in myclodisplastic syndrome. Blood 1992; 80: 1213–1217
- Piacibello W., Sanavio F., Bresso P., Severino A., Carlesso N., Pregno P., Stacchini A., Morelli S., Fubini L., Gallo E., Aglietta M., Ferrero D. Stem cell factor improvement of proliferation and maintenance of heniopoictic progenitors in myelodisplastic syndromes. Leukemia 1994; 8: 250–257
- Glinsmann-Gibson B., Spier C., Baier M., Taetle R., Broudy V. C., List A. F. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodisplastic syndrome. Leukemia 1994; 5: 827–832
- Delwel R., Dorssers L., Touw I., Wagemaker G., Lowenberg B. Human recombinant multi-lineage coony stimulating factor (interleukin 3) : stimulator of acute myeloblastic leukemia progenitor cells in vitro. Blood 1987; 70(1)333–336
- Verhoef G. E. G., Boogaerts M. A. Cytogeneties and its prognostic value in myelodisplastic syndromes. Acta Haematol 1996; 95: 95–101
- Ikeda H., Kanakura Y., Tamaki T., Curiu A., Kitayama H., Ishikawa J., Kamayama J., Yonezawa T., Tarui S., Griffin J. D. Expression and functional role of the proto-oncogene e-kit in acute myelohlastic cells. Blood 1991; 78: 2062–2968
- Bernasconi C., Alessandrino E. P., Bernasconi P., Bonfichi M., Caldera D., Lazzarino M., Canevari A., Brusamolino E., Pagnucco G., Castagnola C. Intensive chemotherapy combined with G-CSF and allogeneic Bone Marrow Transplantation (BMT) in high 1-isk myelodisplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS. Br J Haematol 1996; 93(2)157